Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · AbbVie (ABBV)

AbbVie completes $10.9 billion Apogee acquisition; reaffirms 2026 EPS guidance

Mixed Impact 4 of 5 m&a Written later

AbbVie completed its acquisition of Apogee Therapeutics on September 3, 2026, paying $135.11 per share in cash, or about $10.9 billion in total equity value. AbbVie reaffirmed its 2026 full-year adjusted diluted EPS guidance of $13.87 to $14.07 and its third-quarter guidance of $3.84 to $3.88, but expects the deal to reduce adjusted EPS by $0.14 in 2026 and about $0.46 in 2027, with accretion beginning in 2032.

Key points

  • Apogee shareholders received $135.11 per share in cash, for a total equity value of about $10.9 billion.
  • Apogee's common stock ceased trading on NASDAQ before market open on September 3, 2026.
  • 2026 full-year adjusted diluted EPS guidance of $13.87 to $14.07 was reaffirmed and includes a $0.14 per share dilutive impact from Apogee.
  • The acquisition is expected to reduce adjusted diluted EPS by about $0.46 in 2027, with accretion beginning in 2032.

The filing

CompanyAbbVie (ABBV)
Form8-K, current report
Filed with the SECSep 3, 2026, 8:47 AM ET
Accession number0001104659-26-104940

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:16 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 03, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.